Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis

PHASE2CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

November 29, 2011

Primary Completion Date

August 7, 2016

Study Completion Date

August 7, 2016

Conditions
Ulcerative Colitis
Interventions
DRUG

Etrolizumab

Participants will receive etrolizumab at a dose of 100 mg.

Trial Locations (40)

1073

ENDOMEDIX Kft; Gasztroenterológia Budapest, Budapest

1136

Pannónia Klinika Magánorvosi, Budapest

2065

The Canberra Hospital, Garran

2820

Imeldaziekenhuis, Bonheiden

3000

UZ Leuven Gasthuisberg, Leuven

3004

Alfred Hospital, Melbourne

3050

Royal Melbourne Hospital; Gastroenterology, Parkville

3065

St Vincent's Hospital Melbourne; Department of Gastroenterology, Fitzroy

8011

University of Otago, Christchurch, Christchurch

9000

UZ Gent, Ghent

9024

Petz Aladar County Hosp; 1St Dept. of Internal Med., Győr

9054

Dunedin Hospital; Otago District Health Board, Dunedin

11021

Long Island Clin Rsch Asc, LLP, Great Neck

13353

CAMPUS VIRCHOW-KLINIKUM; Charité Centrum 13; Med. Klinik Abt. Hepatologie u. Gastroenterologie, Berlin

24105

Universitatsklinikum Schleswig Holstein; Klinik fur Allgemeine Innere Medizin, Kiel

30342

Atlanta Gastroenterology Associates, Atlanta

30625

Med. Hochschule Hannover; Gastroenterologie, Hanover

32423

Facharzt für Gastroenterologie, Minden

45219

Consultants for Clin. Rsrch, Cincinnati

55905

Mayo Clinic Cancer Center, Rochester

89081

Univ klinikum Ulm; Medizin Zentrum Innere Medizin I, Ulm

92037

University of California, San Diego, La Jolla

3109601

Rambam Medical Center, Haifa

5262100

The Chaim Sheba Medical Center; Multiple Sclerosis Center, Ramat Gan

6423900

Tel Aviv Sourasky Medical Ctr; Gastroenterology Department, Tel Aviv

9103102

Shaare Zedek Medical Center, Jerusalem

Shaare Zedek Medical Ctr; Dept. of Gastroenterology, Jerusalem

V6Z 2K5

GI Research Institute, Vancouver

N6A 4G5

London Health Sciences Centre; Victoria Hospital, London

N6A 4L6

London Health Sciences Centre, London

L4L 4Y7

Toronto Digest. Disease Asso., Woodbridge

500 12

Poliklinika Iii, Hk; Hepatogatroenterolgy, Hradec Králové

547 69

Oblastni nemocnice Nachod a.s.; Endoskopicke centrum, Náchod

708 52

Fakultni nemocnice Ostrava, Ostrava - Poruba

762 75

Krajska nemocnice Tomase Bati, Zlín

Unknown

Middlemore Hospital, Auckland

0620

Shakespeare Specialist Group, Takapuna

08036

Hospital Clinic I Provincial, Barcelona

HA1 3UJ

St. Mark's Hospital; Inflammatory Bowel Disease Unit, Harrow

NE1 4LP

Royal Victoria Infirmary, Newcastle upon Tyne

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY